Frontier Biotechnologies Inc. (SHA:688221)

Frontier Biotechnologies Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	167.68	248.98	526.66	550.89	800.85	839.09
Trading Asset Securities	559.58	600.53	415.06	690.11	679.36	939.58
Cash & Short-Term Investments	727.26	849.51	941.72	1,241	1,480	1,779
Cash Growth	-15.30%	-9.79%	-24.12%	-16.16%	-16.78%	332.03%
Accounts Receivable	46.13	34.75	63.01	36.14	22.34	31.87
Other Receivables	215.79	227.7	2.37	10.55	1.13	1.1
Receivables	261.92	262.45	65.38	46.68	23.48	32.97
Inventory	62.06	41.06	59	55.61	38.62	13.53
Other Current Assets	25.48	69.6	36.68	62.78	35.2	23
Total Current Assets	1,077	1,223	1,103	1,406	1,578	1,848
Property, Plant & Equipment	409.62	393.31	793.02	728.06	605.76	239.22
Long-Term Investments	24.43	29.96	-	-	-	-
Other Intangible Assets	138.32	149.32	229.18	257.22	258.44	289.49
Long-Term Deferred Charges	1.74	2.03	0.94	2.74	3.12	3.05
Other Long-Term Assets	12.39	14.89	14.21	16.76	87.8	136.36
Total Assets	1,663	1,812	2,140	2,411	2,533	2,516
Accounts Payable	5.39	0.88	1.13	2.69	3.32	2.1
Accrued Expenses	54.81	25.11	37.39	41.84	38.98	34.02
Short-Term Debt	185.99	283.97	202.3	110.64	52.19	14.99
Current Portion of Long-Term Debt	93.75	43.01	104.06	46	227.77	5
Current Portion of Leases	-	0.23	2.4	4.42	5.09	-
Current Income Taxes Payable	-	-	-	-	-	0.06
Current Unearned Revenue	1.85	2.68	5.83	0.06	-	-
Other Current Liabilities	31.76	39.34	27.04	71.58	72.14	56.55
Total Current Liabilities	373.55	395.2	380.16	277.23	399.49	112.71
Long-Term Debt	53.94	79.36	71.42	117.12	7.5	12.5
Long-Term Leases	-	-	0.17	0.45	0.41	-
Long-Term Unearned Revenue	191.76	196.26	329.35	323.54	269.41	250.46
Other Long-Term Liabilities	-	-	16.35	21.08	25.59	-
Total Liabilities	619.25	670.83	797.44	739.41	702.41	375.67
Common Stock	374.58	374.58	374.58	374.58	359.76	359.76
Additional Paid-In Capital	2,723	2,723	2,723	2,723	2,540	2,593
Retained Earnings	-2,054	-1,956	-1,755	-1,426	-1,069	-809.31
Comprehensive Income & Other	0.04	0.02	0.01	0.03	-0.05	-0.03
Total Common Equity	1,044	1,141	1,343	1,671	1,830	2,143
Minority Interest	-	-	-	-	-	-2.42
Shareholders' Equity	1,044	1,141	1,343	1,671	1,830	2,141
Total Liabilities & Equity	1,663	1,812	2,140	2,411	2,533	2,516
Total Debt	333.68	406.56	380.35	278.62	292.96	32.49
Net Cash (Debt)	393.59	442.95	561.37	962.38	1,187	1,746
Net Cash Growth	-3.37%	-21.09%	-41.67%	-18.94%	-32.01%	369.77%
Net Cash Per Share	1.05	1.19	1.50	2.64	3.29	6.05
Filing Date Shares Outstanding	374.58	374.58	374.58	374.58	359.76	359.76
Total Common Shares Outstanding	374.58	374.58	374.58	374.58	359.76	359.76
Working Capital	703.17	827.41	722.63	1,129	1,178	1,735
Book Value Per Share	2.79	3.05	3.58	4.46	5.09	5.96
Tangible Book Value	905.65	991.99	1,114	1,414	1,572	1,854
Tangible Book Value Per Share	2.42	2.65	2.97	3.78	4.37	5.15
Buildings	159.06	159.06	76.22	76.22	-	-
Machinery	128.41	127.73	47.35	45.92	30.44	35.06
Construction In Progress	172.45	147.74	695.97	622.9	582.29	220.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.